Extensive experience with biomedical startup companies and extremely knowledgeable about university tech transfer processes and in-licensing from academic institutions. Sam has licensed 10 technologies from university partners. While at Carilion, Sam was responsible for managing the research that led to the discovery of the OcuCure small antiangiogenic molecules.

Dr. Greven is the Richard Weaver Professor and Chair of the Ophthalmology Dept. at Wake Forest University School of Medicine. He is a member of the American Society of Retinal Specialists, the Retina Society, and the Macula Society. He has been PI on multiple AMD and DR clinical trials and published/spoken internationally on retinal diseases. He has received the Honor Award and Senior Achievement Award from the American Academy of Ophthalmology.

Sunder has over 35 years of experience in creating and growing new businesses in the eye care space. He has been a senior executive of major multinational companies and in start-up ventures. Sunder developed and commercialized the AOSEPT contact lens solution which was acquired by Novartis. He was a member of the Innotech executive team, a venture funded start-up company that went public on the NASDAQ and was acquired by Johnson & Johnson.

Pat has over 30 years of experience in both preclinical and clinical pharmacology. She focuses on safe and efficacious treatments for blinding eye diseases. Pat is a founding member of EyeRx Research, Inc., where she has teamed with ophthalmologists and other scientists to develop several ophthalmic drugs through to clinical trials and the FDA regulatory process. Pat’s team has been awarded 7 patents.